Sinopep

Sinopep develops and manufactures peptide, oligonucleotide, and small molecule APIs for licensed facilities, supported by active Type II Drug Master Files and Letters of Authorization.

Sinopep develops and manufactures peptide, oligonucleotide, and small molecule APIs for licensed facilities, supported by active Type II DMFs and Letters of Authorization.

Sinopep specializes in developing and manufacturing peptide, oligonucleotide, and small molecule NCEs, using solid-phase and liquid-phase synthesis for complex sequences.

End-to-end CDMO support for peptides, oligonucleotides, small molecules, and advanced conjugates, from discovery and process development through multi-ton commercial API and finished drug product, including green synthesis, advanced conjugation chemistries, and immunogenicity assessment.

Wang, Peng, Mengying Jia, Yi Ren, Shiyi Xiong, Shiyang Li, and Chengqing Zhao. Available at SSRN 5358837.

Zhou, L.; Lai, Z.-T.; Lu, M.-K.; Gong, X.-G.; Xie, Y. Biomed. Res. Int. 2008, 2008(1), 736060.

Li, S.; Jiao, J.; Meng, S.; Zhao, C.; Wu, J. Selective Ag⁺ Sensing and Cellular Imaging Based on Hydrophilic Modulated Peptide Probe. Luminescence 2026, 41, e70397.

Gothard, Chris M., and James S. Nowick. The Journal of Organic Chemistry 75.6 (2009): 1822-1830.

Oct 29, 2026 | Press Releases, Sustainability

Sinopep produces GLP-1 receptor agonists at large scale, supporting batches from milligrams to over 200 kilograms.

Oct 29, 2026 | Sustainability, Whitepaper

Leading peptide & oligo CDMO providing development and commercial manufacturing with GMP quality, helping companies scale efficiently.

Allsino Pharmaceutical secures a Silver rating from EcoVadis, a sustainability assessment platform. The recognition highlights the company’s commitment to responsible business practices in pharmaceuticals. EcoVadis evaluates environmental, social, and governance (ESG) performance across global supply chains.

Oct 2026Sinopep-Allsino Biopharmaceutical Co., Ltd.News article

Adalvo and Sinopep form a strategic partnership to collaborate on GLP-1 and oligonucleotide therapeutics development. The alliance integrates Sinopep’s expertise in oligonucleotide-based therapies with Adalvo’s focus on GLP-1 research. Both companies aim to advance innovative treatments in metabolic and genetic disorders through joint efforts.

Oct 2026Sinopep-Allsino Biopharmaceutical Co., Ltd.News article

Sinopep and Allsino showcased their offerings at **CPHI Milan 2026**, engaging with attendees at **Booth 4H7** in Fiera Milano. The event concluded recently, marking the company’s presence in the pharmaceutical industry exhibition. The team expressed gratitude to visitors for their participation.

Oct 2026Sinopep-Allsino Biopharmaceutical Co., Ltd.News article

Contract development and manufacturing organizations (CDMOs) face challenges securing raw materials to meet rising demand for GLP-1 receptor agonist drugs. These injectable medications, driven by high consumer popularity, strain supply chains as CDMOs scale production capacity. The sector is under pressure to ensure consistent availability amid growing patient adoption.

Sep 2025pharmamanufacturing.comNews article